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Fibromyalgia is a chronic syndrome characterized by generalized pain, joint rigidity, intense fatigue, sleep alterations, headache,
spastic colon, craniomandibular dysfunction, anxiety, and depression. The purpose of the present study was to determine whether
massage-myofascial release therapy can improve pain, anxiety, quality of sleep, depression, and quality of life in patients with
ﬁbromyalgia. A randomized controlled clinical trial was performed. Seventy-four ﬁbromyalgia patients were randomly assigned
to experimental (massage-myofascial release therapy) and placebo (sham treatment with disconnected magnotherapy device)
groups. The intervention period was 20weeks. Pain, anxiety, quality of sleep, depression, and quality of life were determined at
baseline,after thelast treatmentsession,and at1monthand 6months.Immediately aftertreatment and at1month,anxietylevels,
quality of sleep, pain, and quality of life were improved in the experimental group over the placebo group. However, at 6months
postintervention, there were only signiﬁcant diﬀerences in the quality of sleep index. Myofascial release techniques improved pain
and quality of life in patients with ﬁbromyalgia.
1.Introduction
Fibromyalgia (FMS) is a chronic syndrome characterized by
generalizedpain,jointrigidity,andintensefatigue.Otherfre-
quently associated symptoms are sleep alterations, headache,
spastic colon, craniomandibular dysfunction, anxiety, and
depression. Fibromyalgia has a negative eﬀect on the quality
of life of patients, who often feel incapable of performing
such basic daily life activities as walking, going up stairs, or
liftingobjects,increasingtheirdisabilityindexandutilization
of health services [1, 2].
The etiology of the disease is currently unknown but sev-
eral hypotheses have been developed, given that ﬁbromyalgia
syndrome is a multidisciplinary problem approached from
diﬀerent perspectives. Histological and histochemical studies
have demonstrated that it is not an inﬂammatory process
[3]. The most widely accepted hypothesis is that chronic
pain in FMS is of muscle origin, although plasma muscle
enzyme levels, electromyographic studies, and muscle biop-
sies have proven completely normal [4–6]. The methodolog-
ical approach to muscle studies has been varied, from muscle
biopsies for structural study to electromyograms and muscle
metabolism studies using spectroscopic nuclear magnetic
resonance (NMR). Results have shown characteristics associ-
atedwithpainperceptionchanges,sleepalterations,decrease
in brain serotonin levels, and abnormalities in microcircu-
lation and muscle energy metabolism [7]. Taken together,
these alterations contribute to neuronal hyperreactivity and
myofascial distress, indicating that the origin of the pain may
be related to myofascial trigger points or musculoskeletal
changes.
Modiﬁcations of adrenocorticotropic hormone levels
and a decrease in plasma serotonin have been reported in
some of these patients, indicating central nervous system2 Evidence-Based Complementary and Alternative Medicine
(CNS) involvement and neurohormonal axis changes. In this
regard, there is evidence of interaction between low sleep
quality and low plasma levels of serotonin, a neurotransmit-
ter that functions in the neuromodulation of sleep, pain, and
mood [8–10]. Various studies have demonstrated that the
perception of pain in FMS is related to CNS modiﬁcations
that translate into the ampliﬁcation of nociceptive impulses
[11]. This phenomenon is designated “central sensitization”
and is believed to result from the plasticity of neuronal
synapses in response to previous painful experiences. Dif-
ferent degrees of central sensitization have been described,
explaining the variations in pain reported by FMS patients.
Although there is no speciﬁc peripheral tissue anatomy
that characterizes ﬁbromyalgia, this does not reduce the
importance of peripheral nociceptive mechanisms [12, 13].
CNS sensitization leads peripheral pain generators to trigger
major nociceptive impulses that will in turn increase central
sensitization. The most frequent peripheral pain generators
in FMS include: myofascial trigger points, degenerative
joint disease, inﬂammatory joint disease, bursitis, ten-
dinitis, development alterations, hypermobility syndrome,
neuropathic pain, injuries, traumas, repeated muscle pulls,
visceral pain, disk herniation, spinal stenosis, and recurrent
cephalalgia [14, 15].
T h e r ei sn oe v i d e n c eo fm u s c l ed i s e a s ei nF M Sb u t
there are reports of dysfunction in intramuscular connective
tissue or fascia; fascial inﬂammation triggers a peripheral
nociceptive stimulus that leads to central sensitization in
FMS [16–18]. Immunohistochemical studies of fascial tissue
biopsies reveal an increase in collagen levels and inﬂamma-
tion mediators in connective tissue surrounding muscle cells
[16]. In line with these ﬁndings, an exploratory and tentative
study suggested the presence of latent and active myofascial
trigger points in patients with FMS and myofascial pain
syndrome [17–20].
1.1. Purpose of the Study. Because the cause of FMS syn-
drome remains unknown, treatment is usually in response
to symptoms. However, the eﬀectiveness of pharmacological
and nonpharmacological treatments has been limited. The
purpose of this study was to determine the beneﬁts of
massage-myofascial release therapy on pain, anxiety, quality
of sleep, depression, and quality of life in patients with FMS.
2. Methods
2.1. Study Design. A randomized controlled trial was per-
formed, with placebo group (FMS patients subjected to a
sham protocol of magnotherapy) and experimental group
(FMS patients who received massage-myofascial release
therapy). The study period was from January 1 2009 to
January 31 2010.
2.2. Setting and Patients. We recruited patients diagnosed
with FMS (by clinicians according to the criteria of the
American College of Rheumatology) [21] who belong
to the Almeria Fibromyalgia Association (AFIAL-Spain).
Inclusion criteria were FMS diagnosis, age from 18 to 65
Table 1: Demographic characteristics of the groups.
Characteristics Experimental
(n=30) Placebo (n=29) P
Mean Age (SD) 49.32 (11.63) 46.29 (12.29) .058
Sex (%)
Female 94.36 96.42 .321
Male 5.64 3.58 .109
Educational level (%)
No school 22 (73.3) 19 (65.5) .131
Primary school 4 (13.3) 7 (24.1) .122
Secondary school 3 (10) 1 (3.4) .314
University school 1 (3.3) 2 (6.9) .629
Work activity (%)
Full-time 12 (40) 9 (31.03) .119
Part-time 7 (23.3) 10 (34.5) .107
Sick leave 2 (6.7) 4 (13.8) .231
Unemployed 9 (30) 6 (20.7) .116
P-value <.05 between experimental and placebo groups.
years (working age range), no regular physical activity, and
agreement to attend evening therapy sessions. Exclusion
criteria were:nonagreement tostudy participation, receipt of
othernonpharmacologictherapies,presenceofcardiac,renal
or hepatic insuﬃciency, cardiovascular event during the
previous year, and presence of peripheral arterial or venous
insuﬃciency, physical or psychological disease, infection,
fever, hypotension, respiratory alterations limiting treatment
application, skin integrity alterations, and failure to comply
with prescribed pharmaceutical therapy [22].
Out of the 231 accessible patients with a medical
diagnosis of FMS, 35 were unable to participate due to
incompatibility with their work schedule and the remaining
196 were subjected to a randomization process to select a
sample of 100 patients; 36 of these did not meet study inclu-
sion criteria, and the remaining 64 were randomly assigned
to an experimental (n=32) or placebo (n=32) group by
using sealed envelopes. Informed consent of patients was
obtained, fulﬁlling the ethical criteria established in the
HelsinkiDeclaration,modiﬁedin2000,forresearchprojects.
In Spain, the current legislation for clinical trials is gathered
in Real Decreto 223/2004 of February 6. The study was
approved by the ethics and research committee of the
University of Almeria.
2.3. Measures. The instruments listed below were used to
measure pain, anxiety, depression, quality of sleep, and
quality of life.
Pain was assessed with the Visual Analog Scale (VAS),
which assesses the pain intensity and degree of relief expe-
rienced by the patient (score of 0=no pain; 10=unbearable
pain). Painful sensitive points were assessed by means of
a pressure algometer (Wagner FPI 10-USA), exerting a
pressure of 4kg. This instrument consists of a sphere, on
which the pressure measurements (10 levels of 0.5Kg each)
are shown, with a rubber end for exertion of the pressure.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Follow of participants in the study.
Table 2: Diﬀerences between groups in numbers of patients with painful tender points (9 tender points I).
Baseline PTP
P
20 Weeks PTP
P
1 Month PTP
P
6M o n t h sP T P
P
Tender
points EG PG EG PG EG PG EG PG
RO 15 22 .173 9 20 .048∗ 11 22 .042∗ 13 21 .098
LO 13 21 .182 8 22 .035∗ 10 23 .032∗ 12 23 .044∗
LCR 19 15 .058 13 16 .683 14 16 .732 16 18 .792
LCL 15 23 .100 5 22 .012∗ 7 21 .023∗ 11 20 .054
RTM 13 22 .101 9 21 .037∗ 12 23 .049∗ 12 22 .049∗
LTM 18 17 .573 10 19 .058 13 23 .051 13 22 .050
RSM 11 20 .063 6 18 .345 7 17 .056 10 18 .108
LSM 14 18 .792 10 17 .108 12 19 .228 15 20 .677
2nd
RR 16 13 .681 8 14 .330 13 15 .796 16 14 .255
∗P-value <.05. Values are presented as numbers of patients with painful tender points. Abbreviations: PTP: painful tender points; EG: experimental group;
PG: placebo group; RO: right occiput; LO: left occiput; LCR: lower cervicals (righ-side); LCL: lower cerivicals (left-side); RTM: right trapezius muscle; LTM:
left trapezius muscle; RSM: right supraspinatus muscle; LSM: left supraspinatus muscle; 2nd RR: second right rib.
The 18 painful sensitive points described by the American
C o l l e g eo fR h e u m a t o l o g yw e r ee v a l u a t e d[ 23]. The index of
internal consistency is 0.56–0.88 for the measurement of the
pain VAS [24].
Anxiety levels were determined with the 40-item State-
Trait Anxiety Inventory (STAI), which measures anxiety as a
stable dimension of personality (trait or tendency to anxiety)
and also includes a state subscale to detect anxiety behaviors.
Subjects report their feelings in general for the trait scale
and how they feel at the time of questionnaire completion
for the state anxiety scale. The state anxiety scale indicates
the feelings or sensations of anxiety (not at all, somewhat,
moderately so, very much so) at a speciﬁc moment in time.
The trait anxiety scale indicates the frequency with which
anxiety is experienced (almost never, sometimes, often,
almost always). Factorial analyses identiﬁed four factors
related to the presence or absence of anxiety in each scale:
presence of state anxiety, absence of state anxiety, presence
of trait anxiety, and absence of trait anxiety. The index of
internalconsistencyis0.90–0.93forthemeasurementofstate
anxiety and 0.84–0.91 for trait anxiety [25].
The state of depression was determined with the Beck
Depression Inventory (BDI), a self-applied 21-item ques-
tionnaire that assesses a wide spectrum of depressive symp-
toms. It focuses on the cognitive components of depression,
which represent around 50% of the total questionnaire4 Evidence-Based Complementary and Alternative Medicine
Table 3: Diﬀerences between groups in numbers of patients with painful tender points (9 tender points II).
Baseline PTP
P
20 Weeks PTP
P
1 Month PTP
P
6M o n t h sP T P
P
Tender
points EG PG EG PG EG PG EG PG
2nd
LR 19 17 .110 9 18 .059 11 20 .058 11 19 .103
RLE 13 21 .098 8 22 .051 12 21 .051 13 22 .063
LLE 11 18 .227 6 19 .032∗ 9 20 .046∗ 10 19 .066
RG 18 16 .110 6 17 .048∗ 8 19 .048∗ 12 18 .353
LG 17 18 .638 7 19 .034∗ 9 19 .059 9 20 .051
RGT 12 17 .680 3 16 .033∗ 6 18 .046∗ 8 18 .048∗
LGT 9 14 .642 4 14 .057 6 16 .058 8 15 .168
RK 14 19 .638 11 20 .063 13 20 .173 14 19 .638
LK 13 20 .173 10 19 .068 11 20 .063 12 21 .058
∗P-value <.05. Values are presented as numbers of patients with painful tender points. Abbreviations: PTP: painful tender points; EG: experimental group;
PG: placebo group; 2nd LR second left rib; RLE: right lateral epicondyle; LLE: left lateral epicondyle; RG: right gluteal muscle; LG: left gluteal muscle; RGT:
right greater trochanter: LGT: left greater trochanter; RK: right knee; LK: left knee.
Table 4: Diﬀerences in quality of life (SF-36 questionnaire) between study groups.
Baseline M (SD)
P
20 Weeks M (SD)
P
1M o n t h sM( S D )
P
6M o n t h sM( S D )
P
SF-
36 EG PG EG PG EG PG EG PG
PF 5.23
(5.36)
50.24
(8.47) .103 46.72
(6.71)
51.03
(8.24) .012∗ 46.84
(7.22)
49.56
(9.32) .049∗ 48.20
(7.43)
51.19
(6.32) .281
PR 25.97
(7.32)
26.36
(6.25) .553 22.91
(7.15)
26.32
(6.29) .026∗ 24.64
(9.46)
28.97
(8.31) .047∗ 25.49
(8.41)
27.53
(6.25) .213
BP 76.56
(6.31)
78.93
(11.43) .196 73.93
(8.21)
77.54
(11.63) .040∗ 75.05
(7.21)
89.93
(14.63) .046∗ 75.63
(8.22)
77.84
(9.66) .293
GH 67.82
(5.21)
68.78
(7.22) .203 65.20
(5.43)
69.85
(6.24) .055 66.81
(6.19)
68.43
(8.21) .093 67.53
(7.24)
68.13
(6.44) .401
V 60.85
(6.41)
59.42
(5.32) .301 63.53
(8.17)
59.99
(9.41) .051 61.64
(8.66)
59.22
(6.25) .055 62.15
(9.32)
58.93
(7.65) .312
SF 64.03
(8.03)
64.43
(13.22) .639 59.55
(4.22)
64.03
(10.15) .028∗ 60.63
(10.81)
63.56
(9.97) .081 61.27
(7.53)
63.96
(9.71) .088
ER 48.98
(8.13)
46.55
(7.32) .049∗ 46.42
(11.32)
47.74
(9.26) .292 50.45
(7.23)
47.02
(6.43) .057 49.11
(7.33)
46.90
(9.38) .219
MH 77.45
(12.31)
81.10
(1.29) .101 78.27
(10.22)
82.02
(11.67) .074 75.01
(11.13)
78.34
(9.46) .082 76.46
(10.12)
80.03
(12.43) .126
∗P-value =.05.Valuesarepresentedasmeansandstandarddeviations(SD).Abbreviations:EG:experimentalgroup;PG:placebogroup;PF:physicalfunction;
PR: physical role; BP: body pain; GH: general health; V: vitality; SF: social function; ER: emotional role; MH: mental health.
Table 5: Diﬀerences between study groups in Pittsburgh sleep quality index score at baseline and after therapy.
Baseline (n=number of patients) 20 Weeks (n=number of patients)
EG PG
P
EG PG
P
PSQI NP MP SP NP MP SP NP MP SP NP MP SP
P S Q 062 4 191 9 . 0 7 2 052 5 31 4 1 2 . 0 5 2
S L 112 8 132 5 . 8 3 6 11 6 1 3 262 1 . 0 4 5 ∗
S D 072 3 112 7 . 0 4 7 ∗ 0 1 41 60 4 2 5. 0 4 1 ∗
H S E 192 0 052 4 . 3 2 1 01 5 1 5 072 2 . 0 7 3
SDI 0 11 19 2 10 17 .223 0 22 8 2 6 21 .051
D D 02 8 202 6 3. 4 9 3 22 6 202 3 6. 0 8 2
∗P-value=.05. Values are shown as n=number of patients with no problems, moderate problems, severe problems. Abbreviations: PSQI: Pittsburgh sleep
quality index; EG: experimental group; PG: placebo group; PSQ: Pittsburgh subjective quality; SL: sleep latency; SD: sleep duration; HSE: habitual sleep
eﬃciency; SDI: sleep disturbance; DD: daily dysfunction; NP: no problems; MP: moderate problems; SP: severe problems.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Comparison between study groups in levels of depression, anxiety, and pain. Values are presented as means with errors bars.
score. Out of the 21 items, 15 refer to ecological-cognitive
symptoms and 6 to somatic-vegetative symptoms; each
item has four response options in order of increasing
symptom severity [26]. The aim of the questionnaire is to
quantify symptoms rather than yield a diagnosis. The total
questionnaire score ranges from 0 to 63 points, and the
usual classiﬁcations are as follows: no depression: 0–9 points;
mild depression: 10–18 points; moderate depression: 19–29
points; severe depression: ≥30 points. The reliability of the
BDIis0.65–0.72andtheChronbach’salphacoeﬃcientis0.82
[27].
The Pittsburgh Quality of Sleep Index Questionnaire
(PSQI) was used to study the quality of sleep. It comprises
24 items; the subject responds to 19 of these items, and6 Evidence-Based Complementary and Alternative Medicine
Table 6: Diﬀerences between study groups in Pittsburgh sleep quality index at 1 months and 6 months after treatments.
1M o n t h s( n=number of patients) 6 Months (n=number of patients)
EG PG P EG PG P
PSQI NP MP SP NP MP SP NP MP SP NP MP SP
PSQ 4 8 18 6 14 9 .106 5 5 20 6 6 7 .061
SL 3 13 14 1 10 18 .122 3 12 15 3 8 18 .213
S D 1 1 11 82 3 2 4. 0 4 1 ∗ 2 1 11 72 0 2 7. 0 4 7 ∗
HSE 3 14 13 1 8 20 .051 1 15 14 1 6 22 .058
SDI 0 15 15 3 5 21 .054 0 14 16 3 5 21 .117
DD 5 16 9 2 17 10 .305 4 12 14 2 21 6 .053
∗P-value = .05. Values are shown as n=number of patients with no problems, moderate problems, severe problems. Abbreviations: PSQI: Pittsburgh sleep
quality index; EG: experimental group; PG: placebo group; PSQ: Pittsburgh subjective quality; SL: sleep latency; SD: sleep duration; HSE: habitual sleep
eﬃciency; SDI: sleep disturbance; DD: daily dysfunction; NP: does not present problems; MP: moderate problems; SP: severe problems.
an individual living in the same dwelling (or hospital
room) responds to the remaining 5. Scores are obtained
on each of seven components of sleep quality: subjective
quality, sleep latency, sleep duration, habitual sleep eﬃ-
ciency, sleep perturbations, use of hypnotic medication, and
daily dysfunction. Each component is scored from 0 to
3( 0 =no problems; 3=severe problems). Hence the total
score (adding component scores) ranges from 0 to 21. The
reliability coeﬃcient of the PSQI is 0.78 [28, 29].
Quality of life was assessed with the 36-item SF-36
Quality of Life Questionnaire on functional state, emotional
well-being, and general health. Functional state is repre-
sented by the dimensions of physical function (10 items),
social function (2 items), role limitations due to physical
problems (4 items), and role limitations due to emotional
problems (3 items). Emotional well-being includes mental
health (5 items), vitality (4 items), and pain (2 items).
Finally, perception of general health (5 items) and changes
in health over time (1 item, not included in the ﬁnal score)
were assessed. For each dimension of the SF-36, items were
codiﬁed, aggregated, and transformed into a scale ranging
from 0 (worst health status) to 100 (optimal health status).
Thus, a higher score in the diﬀerent dimensions indicate a
better health status and/or quality of life. The Chronbach’s
alpha coeﬃcient for this questionnaire is 0.78–0.96 [30].
2.4. Procedure. The experimental group was formed by 30
patients and the control group by 29. In all subjects, pain,
anxiety, depression, quality of sleep, and quality of life scores
were determined before (baseline) and immediately after the
20-week intervention and again at one month and 6 months.
2.4.1. Intervention. The experimental group underwent a
protocol of massage-myofascial release therapy during a
weekly 90-minute session for 20 weeks. The treatment
was applied by a physiotherapist specialized in massage-
myofascial therapy and aimed to release myofascial restric-
tions at the sites of the 18 painful points reported by
the American College of Rheumatology. The protocol was
as follows: massage-myofascial release at insertion of the
temporal muscle, release of falx cerebri by frontal lift, release
of tentorium cerebelli by synchronization of temporals,
assisted release of cervical fascia, release of anterior thoracic
wall, release of pectoral region, lumbosacral decompression,
releaseofglutealfascia,transversalslidingofwristﬂexorsand
ﬁngers, and release of quadriceps fascia [31].
The placebo group underwent a weekly 30-minute
session of disconnected magnetotherapy for 20 weeks. With
the patient in prone position, magnotherapy was applied on
the cervical area (15min) and lumbar area (15min). Placebo
group patients were unaware that they were receiving a sham
treatment.
2.5. Data Analysis. SPSS version 18.0 was used for the
data analyses. After a descriptive study of the demographic
variables, the normal distribution of variables was examined
by means of the Kolmogorov-Smirnov test. We calculated
an imputed score for standardized scales missing ≤10% of
responses.Independentt-testswereusedtocomparebaseline
demographic characteristics between participants and drop-
outs and between the experimental and placebo groups
(randomization test).
Changes in scores for anxiety, pain, depression, and
quality of life were analyzed by using a 2 (Groups: experi-
mental and placebo) ×4 (Time points: baseline, immediately
postintervention, at 1 and 6 months) repeated-measures
analysis of variance (ANOVA). A Student’s t-test for paired
measures was used to determine the eﬀectiveness of treat-
ments. Diﬀerences between study groups were analyzed with
aS t u d e n t ’ st-test for independent samples. P<. 05 was
considered signiﬁcant in all tests.
3. Results
Out of the sixty-four patients enrolled in the study, two
were lost from the experimental group for starting another
treatment and three dropped out of the control group due
to family and personal problems (Figure 1). Therefore, the
study was completed by 30 patients in the experimental
group and 29 in the control group. At baseline, the two
groups did not signiﬁcantly diﬀer in: demographic charac-
teristics (Table 1), mean VAS score for pain (P<. 087), trait
anxiety (P<. 074), state anxiety (P<. 064), BDI (P<. 081),
sensitive points, any SF-36 dimension except for emotionalEvidence-Based Complementary and Alternative Medicine 7
role (P<. 049), or any dimension of the PSQI except for
sleep duration (P<. 047).
3.1. Immediately after 20-Week Intervention. Postinterven-
tion, the experimental group showed a signiﬁcant improve-
ment in VAS score for pain (P<. 043,) versus baseline
and in comparison to the control group (Figure 2). There
were signiﬁcant reductions in sensitive points as measured
by pressure algometer at left lower cervicals (P<. 023), right
g l u t e a lm u s c l e( P<. 038), left gluteal muscle (P<. 043)
and right greater trochanter (P<. 039). No changes were
observed in the placebo group. Tables 2 and 3 show the
signiﬁcant diﬀerences between the groups.
The experimental group also showed a signiﬁcant
improvement in trait anxiety (P<. 041) versus baseline
and in comparison to the placebo group. There were
no diﬀerences in state anxiety or BDI versus baseline or
between groups (Figure 2). Among the SF-36 dimensions,
the experimental group showed signiﬁcant improvements
in physical function (P<. 007), physical role (P<. 039),
body pain (P<. 043), and social function (P<. 048) versus
baseline. Table 4 shows the signiﬁcant diﬀerences between
groups. No changes were observed in the placebo group.
The experimental group showed a signiﬁcant improvement
versus baseline in sleep latency (P<. 041) and sleep duration
(P<. 039) in the PSQI, while no changes were observed in
the placebo group. Table 5 shows the signiﬁcant diﬀerences
between the groups.
3.2. One Month Postintervention. One month postinterven-
tion, the experimental group showed a signiﬁcant improve-
ment in VAS score for pain (P<. 043) versus baseline and in
comparison to the control group (Figure 2) and a signiﬁcant
reduction versus baseline in painful sensitive points at left
lower cervicals (P<. 031), right gluteal muscle (P<. 039),
and right greater trochanter (P<. 044). No changes were
observed in the placebo group.
The experimental group showed a signiﬁcant improve-
ment in trait anxiety (P<. 043) but no signiﬁcant diﬀerences
were found between groups (Figure 2). No diﬀerences were
observedinBDIscoreversusbaselineorbetweengroups.For
the SF-36 dimensions, there were signiﬁcant improvements
in physical function (P<. 01), while no changes were
observed in the placebo group. Table 4 shows the signiﬁcant
diﬀerences between the groups. For the PSQI items, the
experimental group showed a signiﬁcant improvement in
sleep duration versus baseline (P<. 045), while no changes
were observed in the placebo group. Table 6 shows the
signiﬁcant diﬀerences between groups. In the experimental
group, repeated-measures ANOVA showed a signiﬁcant time
× groups interaction for: VAS score for pain (F = 0.396;
P<. 047), trait anxiety (F = 0.403; P<. 045), physical
function (F = 0.771; P<. 028), physical role (F = 0.422;
P<. 044), and body pain (F = 0.633; P<. 047) dimensions
of the SF-36.
3.3. Six Months Postintervention. At 6 months postinterven-
tion, the experimental group showed a signiﬁcant improve-
ment versus baseline (P<. 047) in sleep duration (PSQI)
and for a tender point at right greater trochanter (P<. 048).
Tables 3 and 6 show the signiﬁcant diﬀerences between the
groups. No changes were found in the placebo group.
4. Discussion
In this study, a 20-week massage-myofascial release program
signiﬁcantly improved the pain, anxiety, quality of sleep, and
quality of life in FMS patients. The treatment reduced the
sensitivity to pain at sensitive points, mainly at the lower
cervicals, gluteal muscles, and right greater trochanter.
Fascial entrapment patterns can appear when a body
segment stops receiving appropriate stimuli, establishing a
pathological process with deﬁcient circulation and limita-
tion in nutrient supply to the fundamental substance of
connective tissue, with its consequent densiﬁcation. Because
dense tissue is hypomobile, this situation leads to movement
limitations [31]. Fat accumulation is therefore favored
in the aﬀected body segment, altering the properties of
the connective tissue and perpetuating the dysfunction if
not corrected. Areas of myofascial entrapment are highly
sensitive and painful to all type of stimuli [32].
In the present study, massage-myofascial release therapy
produced no changes in BDI scores. A follow-up period
of more than six months is probably necessary for a
more exhaustive analysis of the bidirectional relationship
between pain and depression in FMS. The presence of
depression may facilitate the expression of active trigger
points and viceversa [17, 18]. Multidisciplinary approaches
have achieved signiﬁcant improvements in depression in
FMS patients, attributed to the synergistic action of the
diﬀerent therapies against pain [33–37]. The comorbidity of
pain and depression may be linked to central sensitization,
in that the persistence of chronic pain and depression may
indicate a common pathogenic mechanism attributable to
alterations of the hypothalamus-hypophyseal-adrenal axis
[38].
The signiﬁcant improvements in SF-36 dimensions,
physical function, and body pain observed after myofascial
release therapy were also reported after aerobic exercise
and multidisciplinary interventions in FMS patients [39–
44]. These studies underlined the importance of motivation
and reinforcement through health education to reduce body
pain and improve quality of life perception. We could ﬁnd
no published reports of a signiﬁcant improvement in state
anxiety through the application of manual therapy alone,
and this was also true in the present study. However, a
multimodal approach has yielded improvements in state
anxiety levels [45, 46], which may be explained by their
positive impact on psychoemotional factors [47]. Anxiety
and stress can aﬀect proteoglycan synthesis and metabolism,
hence interfering with the mechanical properties of connec-
tive tissue. If perpetuation of this phenomenon is combined
with immobility phenomenon, fascial entrapment areas
appear, triggering the emergence of painful points [48]. The
improvements obtained in the PSQI by applying myofascial
release techniques were similar to those obtained by the
manipulation of conjunctive tissue [49]. The release of
fascial restrictions, correcting visceral fascial dysfunction at8 Evidence-Based Complementary and Alternative Medicine
intestinal level, may facilitate sleep by favoring the secretion
of serotonin by platelets. A large number of these patients
have intestinal problems or diseases, which may be due to
neuroendocrine disorders that can aﬀect serotonin secretion
[50].
One study limitation is the exclusion of 35 of the 231
eligible participants due to incompatibility with their work
schedules.Afurtherlimitationisthatpatientswithlesssevere
pain may have been able to improve more rapidly.
5. Conclusions
This study demonstrated that massage-myofascial release
therapy reduces the sensitivity to pain at tender points in
patients with ﬁbromyalgia, improving their pain perception.
Release of fascial restrictions in these patients also reduces
anxiety levels and improves sleep quality, physical function,
and physical role. Massage-myofascial program can be
consideredasanalternativeandcomplementarytherapythat
can achieve transient improvements in the symptoms of
these patients.
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